Response to: 'Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'' by Tampe et al
- PMID: 33980607
- DOI: 10.1136/annrheumdis-2021-220398
Response to: 'Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'' by Tampe et al
Keywords: COVID-19; Rituximab; granulomatosis with polyangiitis; vaccination.
Conflict of interest statement
Competing interests: KLW receives consulting fees from: Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, BMS, Regeneron, Sanofi, AstraZeneca, Novartis.
Comment on
-
Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab.Ann Rheum Dis. 2021 Aug;80(8):1102-1104. doi: 10.1136/annrheumdis-2021-220088. Epub 2021 Mar 4. Ann Rheum Dis. 2021. PMID: 33674264 Free PMC article. No abstract available.
-
Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'.Ann Rheum Dis. 2023 Jun;82(6):e132. doi: 10.1136/annrheumdis-2021-220382. Epub 2021 May 12. Ann Rheum Dis. 2023. PMID: 33980606 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
